Yabao Pharmaceutical Group Co. Ltd. Class A

Yabao Pharmaceutical Group Co. Ltd. Class A

SSSE:600351
6.61
CNY
+0.13
(+2.01%)
0.52EPS
13.06P/E
4.72BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A carries a market capitalization of 4.72B, placing it among publicly traded companies globally. Its enterprise value stands at 3.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.72B
Enterprise Value3.75B

Share Statistics

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A has 692.00M shares outstanding.

Shares Outstanding692.00M

Valuation Ratios

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 13.06. The price-to-sales ratio is 2.15, and the price-to-book ratio stands at 1.71.

PE Ratio13.06
PS Ratio2.15
PB Ratio1.71
P/TBV Ratio1.89

Enterprise Valuation

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A trades at an EV/EBITDA multiple of 8.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.75B versus a market cap of 4.72B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.71
EV / EBITDA8.46
EV / EBIT8.46

Financial Position

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A maintains a current ratio of 3.50, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.14, indicating conservative leverage, while an interest coverage ratio of 499.12 demonstrates strong ability to service its debt obligations.

Current Ratio3.50
Quick Ratio2.08
Debt / Equity0.14
Debt / EBITDA0.01
Interest Coverage499.12

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 642,610.97 in revenue per employee across its workforce of 3,415.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee642,610.97
Employee Count3,415.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A recorded 85.81M in income tax expense. That works out to an effective tax rate of 19.33, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 443.97M, leaving 361.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax85.81M
Effective Tax Rate19.33

Stock Price Statistics

CNY

As of the close on November 17, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A's stock has declined approximately 3.78% over the past 52 weeks. The 50-day moving average sits at 6.84, while the 200-day moving average is 6.65.

52-Week Price Change-3.78%
50-Day Moving Average6.84
200-Day Moving Average6.65

Income Statement

CNY

Over the twelve months ended September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A generated 2.19B in revenue and converted that into 361.52M in net income, yielding earnings per share of 0.52. EBITDA reached 442.67M, while operating income came in at 389.26M.

Revenue2.19B
Gross Profit1.19B
Operating Income389.26M
Pretax Income443.97M
Net Income361.52M
EBITDA442.67M
EBIT442.67M
Earnings Per Share (EPS)0.52

Balance Sheet

CNY

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A holds 917.89M in cash and equivalents against 3.80M in total debt, resulting in a net debt position of -914.45M. Total book value stands at 2.76B, with working capital of 1.11B providing operational flexibility.

Cash & Cash Equivalents917.89M
Total Debt3.80M
Net Debt-914.45M
Equity (Book Value)2.76B
Book Value Per Share3.98
Working Capital1.11B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-33.89M

Margins

Over the twelve months ended September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A posted a gross margin of 54.28, reflecting its pricing power and cost economics. The operating margin of 17.74 and net profit margin of 16.47 provide insight into operational efficiency.

Gross Margin54.28
Operating Margin17.74
Pretax Margin20.23
Profit Margin16.47
EBITDA Margin20.17

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A paid dividends of 0.55 per share. The dividend payout ratio of 107.95 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.73, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Yabao Pharmaceutical Group Co. Ltd. Class A shareholders.

Dividend Per Share0.55
Payout Ratio107.95
Shareholder Yield10.73

Stock Splits

Yabao Pharmaceutical Group Co. Ltd. Class A's most recent stock split took place on May 28, 2010 with a 1:2 split ratio.

Last Split Date5/28/2010
Split Ratio1:2

Scores

As of September 30, 2026, Yabao Pharmaceutical Group Co. Ltd. Class A has an Altman Z-Score of 8.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.17